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ABSTRACT:  Out of all categories, monoclonal antibodies (mAbs), biosimilar, antibody-drug conjugates (ADCs) and 
Fc-fusion proteins attract the most interest due to their strong therapeutic potency and specificity. Because of 
their intrinsic complexity due to a large number of micro-heterogeneities, there is a crucial need of analytical 
methods to provide comprehensive in-depth characterization of these molecules. CE presents some obvious ben-
efits as high resolution separation and miniaturized format to be widely applied to the analysis of biopharmaceu-
ticals. CE is an effective method for the separation of proteins at different levels. capillary gel electrophoresis 
(CGE), capillary isoelectric focusing (cIEF) and capillary zone electrophoresis (CZE) have been particularly relevant 
for the characterization of size and charge variants of intact and reduced mAbs, while CE-MS appears to be a 
promising analytical tool to assess the primary structure of mAbs and related products. This review will be dedi-
cated to detail the current and state-of-the-art CE-based methods for the characterization of mAbs and related 
products.  
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1. INTRODUCTION 
Monoclonal antibodies (mAbs) are highly complex tetrameric glycoproteins that must be extensively analytically 
and structurally characterized to become drug candidates [1, 2]. This is also true for biosimilar [3, 4] and biobetter 
antibodies [5], for glyco-engineered antibodies [6] and for IgG-related products such as Fc-fusion proteins and 
peptides [7, 8], antibody-drug conjugates [9], bi- and multi-specific antibodies [10] and antibody mixtures [11, 12].  
A plethora of separation techniques based both on liquid chromatography and electrophoresis are used for 
antibody characterization and homogeneity assessment [13]. These orthogonal analytical methods aim to sepa-
rate the antibody main isoform from microvariants and process related impurities such as host cell proteins (HCPs) 
[14]. A correct primary structure assessment and extensive glyco-profiling are the cornerstone of antibody char-
acterization. A combination of intact, middle-down, middle-up and bottom-up mass spectrometry (MS) tech-
niques is the workflow of choice to characterize the amino acid sequence and the major post-translational modi-
fications (PTMs) of antibodies [15]. IgG glycans represent an average of only 2−3% of the total antibody mass, but 
they are one of the critical quality attributes for therapeutic candidates [16]. Micro-variants are commonly ob-
served when mAbs are analyzed by charge-based separation techniques such as isoelectric focusing gel electro-
phoresis (IEF), capillary IEF (cIEF), imaged cIEF (icIEF), and ion exchange chromatography (CEX/ AEX). Many of the 
modifications leading to the formation of acidic and basic species have been identified by analyzing fractions col-
lected from chromatography-based methods, with the aim of further analyzing their impact on safety, pharmaco-
kinetics and pharmacodynamics (PK/PD). Those located in antibody complementarity-determining regions (CDRs) 
are often considered to be the most critical because they are surface exposed and often involved in the antigen 
binding [17]. 
In the past decade, several hundreds of papers have been published on mAbs analytical and structural charac-
terization, and the trend will certainly continue to expend in the future. Multiple and complementary liquid chro-
matography, electrophoresis, spectroscopic methods and MS methods are used at all stage of mAbs discovery, 
preclinical and clinical development. Because of its high resolving power, simple instrumentation, miniaturized 
format and superior separation efficiency, capillary electrophoresis (CE) represents a powerful techniques to char-
acterized biomolecules [18]. The different electrophoretic modes that can be employed such as capillary gel elec-
trophoresis (CGE) [19], cIEF, icIEF [20] and capillary zone electrophoresis (CZE)[18], exhibits attractive opportuni-
ties for the characterization of mAbs and related products at different levels such as intact or reduced charge- or 
size-variants, isoforms, glyco-profiling and PTMs and also impurity studies. As the main handicap of CE is known 
to be the poor UV-detection limit, CE is fully suitable for coupling to different very sensitive detection methods 
such as laser induced by fluorescence (LIF) [19] and MS [21, 22]. Some reviews assessed that CE-based methods 
as efficient techniques for the characterization and quality control of biomolecules are fully implemented in bio-
pharmaceutical industry [13, 23-29]. Here we review the current and state-of-the art electrophoretic methods 
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relevant in biopharmaceutical field of applications from the year 2010 to 2015. We focused on the characterization 
of mAbs and the related product as biosimilars, ADCs and Fc-fusion proteins which represents today the fast grow-
ing class of biotherapeutic products. 
 
2. Capillary Gel Electrophoresis (CGE) 
2.1 Technical considerations 
Since the 90s, CGE has known a significant concern for the characterization of proteins. Currently, this method 
is recognized as an essential analytical technique especially in the biopharmaceutical industry for the characteri-
zation of mAbs. CGE is a method based on the same mechanism as sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). After complete reaction between SDS and proteins, SDS-protein complexes with the 
same negative charge are formed allowing electrophoretic separation in a sieving medium only based on their 
hydrodynamic radius. SDS-PAGE has been used for size-based protein separation routinely. However, this methods 
is also known as labor-intensive, time consuming and lacking reproducibility. The adaptation of SDS-PAGE to a 
capillary format permits to reduce drawbacks and brings some advantages as ease of handling, automated proce-
dure, short analysis time and improved resolution. The transfer of SDS-PAGE to CGE is based on the replacement 
of the traditional slab gel by soluble polymers used as replaceable molecular sieve. This allows the separation 
based on hydrodynamic radius differences directly into the capillary. Proof that this method is now routinely es-
tablished in industries, several companies commercialized sieving kits to perform CGE. In this electrophoretic 
mode and to assure that the separation is strictly based on the size differences, electroosmotic flow (EOF) has to 
be suppressed. The vast majority of reported CGE analysis (Table 1) were performed using bare fused silica capil-
lary (BFS). This can be explained by the use of commercial sieving kits which contain some additives to suppress 
EOF. For example, the Beckman Coulter SDS-Mw gel buffer includes a high concentration of Tris-borate to elimi-
nate EOF. However, other strategies have been described to suppress EOF and to reduce possible adsorption of 
protein on the inner capillary wall. The article published by Szabo et al reported the use of a linear polyacrylamide 
(LPA) neutral coating to enhance separation efficiency for rapid and high resolution glycan analysis of mAbs [30] . 
Other neutral capillary coated are described as hydroxypropyl cellulose (HPC) [31], Polyvinyl alcohol (PVA) [32, 33] 
and some commercial solution [34-43].  
CGE is classically coupled with UV or fluorescence detection. Using a UV detection, applied wavelengths are 
generally 220 nm and more rarely 200 nm, 214 nm and 280 nm.  Concerning fluorescence detection, laser-induced 
fluorescence (LIF) has been employed to improved sensitivity. The most common condition for CGE-LIF analysis 
consist to the use of a laser operating at 488 nm for fluorescence excitation with the resulting emission signal 
monitored at 520 or 560 nm. CGE-LIF of 8-Aminopyrene-1,3,6-trisulfonic-acid (APTS) labeled N-Glycan appears to 
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be a methods of choice for the determination of mAbs N-glycan profiles [35, 36]. Indeed, APTS reaction with 
proteins allows the derivation of a fluorophoric group and the addition of three negative charges in the glycan 
moety. With these modifications, electrophoretic separation can be obtained faster, with a greater efficiency and 
a higher sensitivity.  Other strategies have been described to label N-glycan. Michels et al developed a fluorescent 
derivatization method using 3-(2-furoyl)-quinoline-2-carboxaldehyde (FQ) as fluorogenic reagent for mAb analysis 
[44]. The same group described a quantitative impurity analysis of mAb size heterogeneity also using FQ labeling 
[45]. More recently, Reusch et al performed a comparative study of APTS and 8-aminonaphthalene-1, 3, 6-trisul-
fonate (ANTS) labeled glycan. All of the methods showed excellent precision and accuracy. Some differences were 
observed, particularly with regard to the detection and quantitation of minor glycan species [35].  
 
2.2 Applications 
For the characterization of mAbs and their related products, CGE is commonly used for protein size heterogene-
ity, purity, assessment of product fragment impurities characterization and aggregation and N-glycan profiling. 
Table 1 summarized applications of CGE in mAbs and related products in 2010-2015. Size heterogeneity represents 
one of the most important application of CGE for mAbs characterization. In 2012, Shi et al proposed a comparison 
between SDS-PAGE and CGE in mAb purity analysis. This work based on the size heterogeneity analysis reported 
several advantages of CGE especially in terms of accuracy and resolution of size determination as well quantitative 
performance [46]. Visser et al performed a comparability study between innovator approved product and biosim-
ilar candidate of rituximab [47]. Using different methods including the size heterogeneity of intact mAb with CGE, 
they concluded that biosimilar candidate and originator rituximab are pharmacologically comparable with regard 
to anti-tumor activity, pharmacokinetic exposure and B-cell depletion. The same year, Glover et al described a size 
heterogeneity study of intact and reduced mAbs to assess the compatibility and the stability between pertuzumab 
and trastuzumab in intravenous infusion bags for coadministration [48]. Using different method as CGE-LIF, CZE 
and icIEF, they obtained results demonstrating no observable differences for the analysis of per-
tuzumab/trastuzumab mixtures store up to 24h at either 5°C of 30°C (Figure 1). As Glover et al, numerous of 
publications described size heterogeneity of reduced mAbs (Table 1). Indeed, changes in molecular composition 
result in alterations of functional performance, therefore quality control and validation of therapeutic or diagnos-
tic protein is essential. Applying reduction step in the sample preparation using a reducing reagent like tris(2-
carboxyethyl)phosphine (TCEP) or dithiothreitol (DTT) which allow to reduce disulfide bonds of mAbs; light chain, 
heavy chain and post-translational modification (PTM) can be determined. Cherkaoui et al described a CGE 
method to evaluate the chemical integrity of mAbs during the coupling to microparticles surface by tracking re-
duction fragments [49]. They followed with a great accuracy the reduction of mAbs in all intermediate isoforms 
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down to single heavy and light chains. In 2013, Yin et al used CGE-LIF with reducing conditions for the characteri-
zation of mAbs between in vitro and in vivo time-course studies [50]. They demonstrated that in vivo mAbs mod-
ification cations are not fully represented by in vitro phosphate buffer or plasma incubation. To further improve 
the performance of CGE, Szekely et al proposed a generally applicable multi-capillary SDS-gel electrophoresis pro-
cess for the analysis of mAbs for high throughput quality control. They adapted CGE method for quality analysis 
under reducing conditions [51]. Finally, Yagi et al proposed a quality control of mAbs using microchip electropho-
resis sodium dodecyl sulfate (ME-SDS) [52]. The intrinsic properties of the microchip (separation channel measur-
ing 14 mm in length and 31 µm in width, high efficiency) make the ME-SDS a powerful methods in terms of mini-
mized analysis time (< 40s). Comparison study between ME-SDS and CGE on the analysis of degradation species 
from heat stressed mAbs showed similar results in terms of purity relative quantitation values and then introduces 
ME-SDS as an alternative method to the commonly used CGE methods.  
 
Figure 1. CE-LIF analysis trace of the APTS-labeled N-glycan profile of the Protein Test Article. The 
20 most abundant peaks were integrated in all the submitted profiles and their migration times and rela-
tive and total areas were then used to determine internal precision and reproducibility of the N-glycan 
mapping assay. The right panel shows the corresponding GUCE values for all integrated peaks in their 
migration order, as well as the name of all identified structures using Oxford notation. Reprinted from 
[34]. Copyright (2015), Taylor and Francis Group.  
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N-glycan profiling represent another important field of applications using CGE for mAbs characterization. As 
described in the technical consideration section, CGE-LIF of APTS labeled N-Glycans represents a reference meth-
ods for the determination of mAbs N-glycan profiles. Wacker et al described the analysis of mAbs glycosylation 
profiles using CGE-LIF. They performed lot-to-lot variability study on major oligosaccharide profiles as quality con-
trol and noted variability of core-fucosylated forms [43]. In 2013, Hamm et al developed a CGE-LIF method to 
identify all the major and most of the minor glycans in a mAbs produced in a NS0 cells using an important numbers 
of glycan standards [33]. To further enhance the performances of N-glycan analysis using CGE in terms of analysis 
time, Reusch et al proposed a method using a DNA analyzer to perform high-throughput glycosylation analysis 
[53]. They showed that CGE-LIF analysis with DNA analyzer can generate data that help to keep a production pro-
cess within the desired design space and assess that a comparable drug substance is being produced after process 
changes. More recently, Szekrényes et al performed an inter-laboratory study composed by biopharmaceutical 
companies, universities, analytical contract laboratories and national authorities in the United States, Europe and 
Asia, to evaluate the reproducibility of sample preparation and analysis of N-glycan using CGE-LIF. Results demon-
strated low variability and high reproducibility, both within any given site as well across all sites. This work indicates 
that CGE-LIF method can be established as a standard N-glycan analysis platform appropriate for general use 
(clone selection, process development, lot release, etc.) within the industry [34]. Even if mAbs represent the major 
class of biotherapeutics analyzed by CGE, some articles on ADCs and Fc-fusion proteins begin to be published. 
Indeed, Le et al described the profiling of a based ADCs using different analytical methods (hydrophobic interac-
tion chromatography (HIC), CGE, HPLC). They developed a mathematical approach using inputs from CGE and HIC 
to determine the positional isomer distribution within a population of ADCs [54]. Concerning Fc-Fusion protein, 
Hapuarachchi et al developed with success a non-reducing CGE method to monitor disulfide scrambled forms 
during purification process [55] and Wang et al studied the characterization of Fc-fusion protein aggregation [37]. 
Implementation of CGE in biopharmaceutical industries is illustrated by the numbers of these articles published 
by scientists coming from R&D departments of companies. CGE method are applied to control the consistency, 
purity and stability of mAbs in the quality control laboratories of Genentech, Merk, Pfizer, Amgen, Roche, Sandoz 
and Bracco for example. 
 
3. Capillary Isoelectric focusing (cIEF) and imaged cIEF (icIEF) 
3.1 Technical considerations 
Similar to the development of CGE according to SDS-PAGE, cIEF is a method based on the mechanism of IEF slab 
gel. The separation of the proteins is based on their isoelectric points (pIs) in a capillary [56]. The classical workflow 
consists of the use of a basic catholyte, generally sodium hydroxide, placed at the cathode and an acidic anolyte, 
generally phosphoric acid, placed at the anode. A mixture of ampholytes and sample filled up the whole capillary. 
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Applying an electrical field and due to ampholytes properties, a pH gradient is established in the capillary. As a 
first step, protein focused along the pH gradient until the region with an equal value between the local pH and it 
own pI. In this region, the electrophoretic mobility of the sample is zero due to the absence of apparent charge 
bearing by the protein. As a second step, electrophoretic or hydrodynamic mobilization is implemented to force 
the sample to move toward the UV detection. However, the mobilization step could have negative effects on the 
migration time and on the resolution due to possible peak broadening. Because of these drawbacks, whole-col-
umn imaging cIEF (icIEF) has been established to achieve faster separation with greater resolution, better repro-
ducibility and reduced sample volume. Indeed, the short capillary length (5 cm) leading to reduce analysis time 
and then allows to perform high-throughput experiments. In addition, using icIEF enabled real-time monitoring of 
the focusing process. Then no mobilization step is useful in icIEF workflow. Presently, icIEF is becoming a reference 
method for the characterization of biotherapeutics.  
To ensure good focusing process in cIEF and icIEF, no hydrodynamic pressure should be applied and EOF has to 
be suppressed. To eliminate EOF, neutral capillaries consisting to neutralize inner surface of capillary with dynamic 
or permanent coating were used (Table 1). Concerning icIEF, the most popular commercial instrument iCE280 
proposed a neutral fluorocarbon capillary which is used in every reports.  
Large cut-off is observed because of the strong absorbance of ampholytes at lower wavelengths, almost all cur-
rent cIEF and icIEF use UV detection at 280 nm. For cIEF, on-line UV detector are available in all commercial CE 
apparatus. Regarding icIEF, real-time monitoring is performed using a CCD camera. To further improve the perfor-
mance of cIEF in terms of sensitivity, Michels et al described a multiplexed icIEF immunoassay with chemilumines-
cence detection for the characterization of mAbs [57]. With different steps of immobilization and conjugation, 
they were capable of detecting product impurities even in the presence of excess host cell protein lysate eliminat-
ing any sample clean up before analysis. Mass spectrometry detection (MS) also appears to be a good candidate 
to enhance the sensitivity. The hyphenation between cIEF and MS allowed to perform separation based on pIs 
and m/z ratio and then to obtain additional structural information. However, due to the presence of salts and 
ampholytes, technical issues curbed the development of this coupling. In 2012, Zhu et al realized a rapid and 
reproducible cIEF-MS method for host cell protein analysis of mAbs [58]. After optimization of the anolyte, cath-
olyte and sheath liquid, they performed the identification of 3.5 pmol of BSA digest which highlights the potential 
of this coupling.  
 
3.2 Applications.  
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cIEF and icIEF has become reference methods for the characterization of charge heterogeneity for biopharmaceu-
tical companies. Intact and reduced therapeutics likewise PTMs can be identified using this electrophoretic mode. 
Table 1 summarized applications of cIEF and icIEF in mAbs and related products in 2010-2015.  
In 2011, Lin et al reported a sensitive cIEF method for determining the charge heterogeneity of mAbs [59]. Under 
optimized conditions they observed the separation of both acidic and basic species of the mAbs. While concen-
tration range of 0.03-0.20 mg/mL were obtained, the method also was used for C-terminal lysine variants charac-
terization and glycosylation profile analysis. More recently, Bonn et al proposed a cIEF method for the develop-
ment of robust protein reagent characterization in the clinical immunodiagnostic [60]. They optimized methods 
to achieve as much as 20-fold increase in the number of consecutive runs before capillary degradation. cIEF 
method was developed for confident identification of differences in charge-related characteristics of proteins.  The 
same year, Cao et al described a cIEF analysis of trastuzumab biosimilar in terms of charge profiling and stability 
testing [61]. They realized optimization on focusing time and separation temperature to get a robust method to 
analyze charge variants. They reported that this method can be applied to evaluate stability, determination of lot 
consistency and purity assessment, and concluded that cIEF was a promising tool for the routine analysis of ther-
apeutic mAbs. This conclusion can be illustrated by the work of Suba et al which considered that cIEF is a basic 
and highly accurate routine analytical tool to prove identity of protein drugs in quality control and release tests in 
biopharmaceutical industries especially with the use of commercial standardized kits [62]. However, they also 
proved that it is still possible to developed and validated cIEF methods for identification testing of mAbs drug 
product. Their method was validated according to the recent ICH guidelines (Q2(R1)). Another recent work per-
formed by Raymond et al about the production of α2,6-sialytated IgG1 in CHO cells proved the usefulness of cIEF 
as part of other analytical methods in the characterization of therapeutic proteins [63]. Authors performed cIEF 
to estimate the nature of the sialic acid linkage by sequential sialidase digestions. To assess cIEF as a reference 
method in biopharmaceutical industries, Salas-Solano et al organized an inter-laboratory comparison [64]. Inter-
national team of 12 laboratories from 10 independent biopharmaceutical companies in the United States and 
Switzerland were formed to evaluate the precision and robustness of cIEF to determine the charge heterogeneity 
of mAbs. The different laboratories determined the apparent pI and the relative distribution of the charge isoforms 
of mAbs. They concluded in a validation of the appropriate use of cIEF in the biopharmaceutical industry in support 
of regulatory submissions.  
An analogous inter-laboratory study was performed by the same group on the robustness of icIEF technique for 
the analysis of mAb [65]. Results showed an important similarity with the precedent inter-laboratory study [64]. 
They concluded that icIEF is a robust technology (i) to determine the charge heterogeneity of mAb, (ii) to be used 
as an alternative or complementary methodology to conventional cIEF technology and (iii) to be a reference 
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method both in process development and quality control of biopharmaceuticals. Numbers of papers illustrated 
the use of this technique in the process development [39, 66]. To further improve the performance of mAbs char-
acterization using cIEF, Meert et al performed mAb charge heterogeneity study by preparative immobilized pH 
gradients (IPG) [67]. They realized IPG-IEF fractionation followed by cIEF analysis. Results extended characteriza-
tion to elucidate the composition of the acidic, main, and basic species observed in the cIEF profile. Dada et al 
reported a similar study using icIEF in place of cIEF [68].   
To evaluate the charge heterogeneity of mAbs with shorten analysis time and in an easier manner, Kinoshita et al 
developed a microchip icIEF (mcIEF) [69]. Authors compared their method with reference cIEF technique. Results 
showed a decrease by 10-fold analysis time and an excellent correlation of calculated pI values and percent relative 
amounts of each charge variants. However, they confessed the lack of automation and the need of improvements 
in functionalization for a commercial use in the biopharmaceutical companies.  
Similar to CGE analysis, mAbs represents the major class of biotherapeutics analyzed by cIEF and icIEF. However 
in 2012, Anderson et al demonstrated the applicability of an icIEF method for the charge heterogeneity of a heavily 
sialylated Fc-fusion protein for biosimilar development [70]. More recently, Wu et al performed the structural 
characterization of a Fc-fusion protein named conbercept by different analytical methods. They measured the pI 
of deglycosylated conbercept using cIEF method [71]. Valierre-Douglass et al reported the charge heterogeneity 
study of heat-stressed mAbs and ADCs using icIEF [72]. They observed important variation of basic variants with 
increasing storage temperature (Figure 2). This article and some others prove that cIEF and icIEF can be imple-
mented in the analysis of charge heterogeneity in ADCs [73, 74].    
 
4. Capillary Zone Electrophoresis (CZE) 
4.1 Technical considerations 
CZE is known as the most straightforward and popular electrophoretic mode used. The separation is based on the 
difference of electrophoretic migration of analytes in a background electrolyte (BGE) depending on their charge-
to-size ratio [75]. The classical workflow consists to fill up the capillary with BGE. After hydrodynamic or electro-
kinetic injection of sample, an electrical field is applied allowing the electrophoretic migration of analytes. The 
most common used detection mode is UV detection mainly fixed at 200 nm or 214 nm for mAbs characterization 
(Table 1). An important issue of CZE with a UV detection is the poor sensitivity. However, one advantage of CZE, 
as compared to CGE and cIEF, is on the better compatibility with MS detection. Despite some issues about the 
nature of BGE (high salt concentration, volatility…), MS detection enhances structural characterization of sample. 
A complete section about the hyphenation between CE and MS will be dedicated further in this review.  
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Similar to CGE and cIEF, charge variants characterization of mAbs using CZE needs to be performed without or 
with a reverse EOF. 
 
 Figure 2. (a) icIEF electropherograms of mAb-1 after 10 days PBS, plasma incubation, and in vivo circulation. Elec-
tropherograms are normalized based on the main peak. The relative percentage of the acidic variants is dramati-
cally increased during plasma incubation. Plasma control is labeled as “blank”. (b) The icIEF analysis of mAb-1 
shows an increase in the acidic peaks during PBS and plasma incubation, and in vivo circulation. Each time point 
for PBS and plasma-incubated samples are in triplicate. Error bars represents standard deviations. Acidic variants 
increase with rate of 0.9%, 2.9%, and 2.1% per day during PBS (▲), plasma (■) incubation, in vivo circulation (●), 
respectively. Reprinted from [50]. Copyright (2013), Springer. 
 
Moreover, due to the negatively charged silanols surface of classical BFS, positively charged proteins will tend to 
interact and then adsorb to the inner capillary wall. These phenomena involve significant decrease of electropho-
retic resolution caused by peak broadening. Different approaches were described to reduce protein adsorption.  
The most frequently applied strategy consists to shield the protein from the BFS by the modification of the inner 
surface of capillary with a dynamic or a permanent coating. Due to their ease of use, dynamic coatings, as hydrox-
ypropyl-methyl cellulose (HPMC) or polybren (PB), are often set up for the characterization of charge heterogene-
ity of mAbs (Table 1). As buffer additives, dynamic coatings adsorb the surface of the capillary during the electro-
phoretic separation but need regular regeneration step. Another way is the use of permanent coatings. Indeed, 
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to avoid regeneration step and possible release which can compromise the compatibility with MS detection, per-
manent coating, consisting to covalent linkage to the capillary wall, appears to be the best option. Many proce-
dures are described in the literature to realize home-made coatings [76]. Note that commercial capillaries also are 
available. An important paper about static coating performances (commercial or not) for the analysis of mAbs by 
CZE has been reported by Gassner et al [77]. Major trends were observed as for example (i), for positive coating 
the EOF and the mAb effective mobility need to be relatively close and (ii) for neutral coating, EOF has to be near 
zero to obtain the best resolution. As a general conclusion, authors showed that no coatings totally eliminates 
protein adsorption and that separation performances are strongly dependent of BGE composition and BGE pH. As 
a solution to enhance the reduction of protein adsorption, some reports described the use of a modifier, as tri-
ethylenetetratmine (TETA) [78-80] or Tween 20 [77], directly added to the BGE.  
Finally, to further improve the performance of CZE methods, microchip zone electrophoresis (MZE) was developed 
to allow the characterization of mAbs charge variants with a drastic reduction of analysis time. Different commer-
cial devices are available coupled with UV, MS or chemiluminescence detection (Table 1).  
 
Figure 3. Effect of EACA concentration on the separation of IgG1 and IgG2 mAbs in a bare fused silica capillary. 
Bare capillary (40 + 10) cm × 50 μm i.d.; capillary temperature 25 °C; separation buffer (A) 50, (B) 100, (C) 200, (D) 
400, and (E) 600 mM EACA-acetic acid, 0.1% HPMC, pH 5.4; voltage 24 kV; injection 0.5 psi × 5 s; detection UV 214 
nm. Peak identity: peak 1, histidine; peak 2, IgG1 mAb; peaks 3 and 4, IgG2 mAbs. Reprinted from [78]. Copyright 
(2010) American Chemical Society. 
 
4.2 Applications.  
As compared to CGE and cIEF, mAbs remain relatively less investigated by CZE, probably due to the protein 
adsorption issues previously described. However, since 2010, a great number of reports described CZE-based 
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methods for the characterization of mAbs charges variants for the quality control of biopharmaceuticals compa-
nies in terms of purity, quantitation and stability testing. Table 1 summarizes applications of CZE articles for mAbs 
and related products in 2010-2015. Precursor in this field of application, Ruesch’s group from Pfizer reported two 
major articles on the separation of intact mAbs charge variants using CZE [78, 79]. They developed experimental 
conditions which to date represent a reference for the analysis of mAbs using CZE with a UV detection. First of all, 
they optimized the BGE pH between 4.5 and 6.0. They demonstrated that pH is a major parameter to increase 
selectivity of charge variants separation. Second of all, they used a BGE based on ε-aminocaproic acid (EACA). 
EACA is an ampholytic compound which allow to decrease adsorption as compared to classical buffer (Figure 3). 
And finally, in the aim to assess the robustness of the method, they added HPMC and TETA in the BGE to perform 
a dynamic coating and to nearly cancel any protein adsorption. Currently, significant number of reports of CZE-
based methods about charge variants of mAbs implement BGE composed of EACA at pH 4.5 to 6.0. Only the con-
centration of EACA and the nature of coating and additives can vary [48, 77, 80-83]. To evaluate CZE as a reference 
method in biopharmaceutical industry, Moritz et al organized an inter-company study to assess CZE for charge 
heterogeneity testing of mAbs. They proposed a generic CZE method [80] to 11 participating labs. It was shown 
that CZE is applicable across a broad pI range between 7.4 and 9.5. Coefficient of correlation for linearity, precision 
by repeatability and accuracy by recovery were 0.99 and around 1% and 100% respectively. This demonstrates 
that CZE is suitable as a new powerful platform technology for the charge heterogeneity testing of mAbs in quality 
control laboratories of biopharmaceutical companies. Glover et al illustrated this conclusion by the use of CZE as 
an orthogonal method in the stability study of pertuzumab and trastuzumab admixture in intravenous infusion 
bag [48]. CZE as well as CGE and icIEF analysis were implemented to conclude of no observable differences in the 
pertuzumab/trastuzumab mixtures store up to 24h at either 5°C of 30°C. The same year, Espinosa-de la Garza et 
al used CZE as an analytical platform to characterize charge heterogeneity of mAbs and biosimilar candidates (Fig-
ure 4) [83]. Despite a good robustness of the method, they showed the need of orthogonal methods to obtain 
structural information and then to assess biosimilarity. To further improve the performance of CZE separation in 
terms of analysis time, Wheeler et al [84] and Han et al [82] proposed MZE methods for high throughput profiling 
of charge heterogeneity in mAb. MZE-based methods achieved from 8- to 90-fold faster separation time over 
conventional methods while maintaining comparable resolution and profiles of charge variant distributions. In 
another work, Antes et al proved the suitability of MZE method for impurity testing of mAbs [85]. They compared 
their method to conventional SDS-PAGE and concluded on the MZE advantages in terms of faster separation and 
convenience of handling the microfluidics-based technology. Finally, Jacoulet et al proposed a fast and reliable CZE 
method combined to a cationic capillary coating to identify the most widely used mAbs for cancer therapy [86]. 
Very satisfactory RSDs and intraday RSDs of mAbs retention time (less than 0.60% and 1.3% respectively) were 
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obtained. This work demonstrates the potential of CZE to be suitable for rapid identification of mAbs for routine 
application in hospital.    
 
Figure 4. Comparison of microchip CZE (a) and conventional CZE (b) for five marketed antibody therapeutics. The 
main peak pI values determined by icIEF are indicated. For mAb C, the pI values of the three major peaks from left 
to right are 7.81, 7.63, and 7.46, respectively. Reprinted from [82]. Copyright (2011) American Chemical Society.  
        
    5. Capillary electrophoresis – Mass spectrometry (CE-MS) 
 5.1 Technical considerations 
As the introduction of electrospray ionization (ESI-MS) and matrix assisted laser desorption ionization (MALDI-MS) 
mass spectrometry extended the field of application of MS to biomolecules, CE appeared rationally as a hyphen-
ated separation technique potentially enabling the analysis of complex samples. Indeed among other type of ap-
plication, CE in its different separation modes demonstrated to be particularly adapted to separate biomolecules 
such as ribonucleic acids, peptides or proteins. Therefore capillary electrophoresis coupled to mass spectrometry 
(CE-MS) was implemented shortly after the introduction of these ionization techniques [87]. For CE-MS coupling 
implementation, the major constraint lies in the necessity to maintain the electric field to perform the electro-
phoretic separation while the capillary outlet has to be positioned inside the source. To overcome this limitation, 
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several interfacing designs have been developed by different research groups. Early developed CE-MS interfacing 
systems relied on a conductive sheath-liquid, connected to the outlet electrode of the CE system, continuously 
injected to maintain the continuity of the electric field. Considering the limited volume of sample that can be 
injected onto the capillary, the dilution effect generated by the addition of the sheath-liquid tends to lower the 
sensitivity therefore going against one of the major advantage of MS. However it is important to note that inten-
sive progress have been made in the last decade regarding CE-MS interfacing. These efforts have led to the com-
mercial introduction of several CE-MS interfaces allowing to perform highly sensitive CE-MS experiments which 
were previously reserved to research groups possessing CE-MS hyphenation specific expertise [88-90].  
Currently CE-ESI-MS is by far the most common type of coupling implemented in CE-MS experiments. Indeed op-
erating conditions of CE are compatible with online coupling with ESI-MS. CE-ESI-MS interfaces can be sorted in 
three different categories based on the principle used to maintain the electric field continuity: sheath-liquid inter-
faces, liquid junction interfaces and sheathless interfaces. Recently, Kleparnik published a review describing in 
details the different methodologies and recent developments in CE-ESI-MS interfacing [91]. Due to its intrinsic 
characteristics, CE appears as particularly favorable to the ESI ionization process. EOF generated during CE exper-
iments represents a few tenths of nL/min, depending on the nature of the BGE used, which is suitable with the 
formation of a nanoESI guaranteeing an optimal ionization efficiency. Additionally, capillary inner diameter is com-
monly below 100 µm which allows the production of thin droplets and favors ions production. Recent progress 
achieved in CE-ESI-MS interfacing enables to take the most from the characteristics of both techniques and insti-
gate the interest for CE-ESI-MS analysis especially due to the different selectivity provided by the electrokinetically 
driven separation. CE-MS analysis can be envisage for the characterization of mAbs on every structure level from 
the quaternary structure down to the primary structure and even post-translational modifications characteriza-
tion. 
 
5.2 Applications 
5.2.1 Amino acid sequence characterization and peptide mapping 
Although produced using highly accurate recombinant technologies, mAbs amino acid requires to be characterized 
to ensure the safety of the product and prevent the occurrence of amino acid substitution due to variation during 
the production or storage process for example. Biacchi et al described the development of an offline CZE-MALDI-
MS system allowing the automatic deposition of the CZE outlet directly of the MALDI plate followed by matrix 
deposition. The CZE-MALDI-MS method developed was used to perform the peptide mapping of trastuzumab 
showing sequence coverage of 92% and 100% respectively for the heavy chain (HC) and the light chain (LC) [92]. 
Peptide mapping can also be performed using CZE-ESI-MS, Gennaro et al showed the analysis of Lys-C digest for 
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several mAbs, in combination with LC-MS analysis, to characterize completely the amino acid sequences of the 
studied mAbs demonstrating the interest of using in concomitance the selectivity of both techniques because of 
their complementarity [93]. Whitmore et al used a sheathless CE-ESI-MS analysis to perform the peptide mapping 
of therapeutic mAbs through tryptic digestion. Results obtained were compared to the peptide mapping results 
observed using LC-MS and sheath-liquid CZE-ESI-MS. Results reported demonstrate the possibility to obtain the 
complete sequence coverage using sheathless CZE-ESI-MS. Data generated showed the characteristics of CZE to 
separate short hydrophilic peptides (down to single amino acids) which tend to be difficult to identify in LC-MS 
experiments because of their elution in void volume [94]. Gahoual et al developed a methodology implementing 
sheathless CZE-ESI-MS/MS for the characterization of several mAbs including trastuzumab and cetuximab. This 
method relies on an optimized sample preparation protocol enhancing digestion efficiency and improving sample 
compatibility with the CZE separation conditions. This method integrates tandem MS to base peptide identifica-
tion on mass measurement in parallel with fragmentation spectra reinforcing the confidence of the identification 
and giving precious information regarding the amino acid sequence. Results described proved from a single injec-
tion corresponding to 16 ng of digested mAbs to systematically obtained 100% sequence coverage considering 
strictly peptides without miscleavages [95]. Also data allowed to characterize simultaneously to the amino acid 
sequence, different type of post-translational modifications hotspots including glycosylation, N-terminal glutamic 
acid cyclization, methionine oxidation, asparagine deamidation and aspartic isomerization. Results showed in the 
case of PTMs characterization, the possibility to separate the modified peptides from its intact homologous due 
to the separation selectivity of CZE therefore improving sensitivity and enabling confident estimation of modifica-
tion levels by preventing the occurrence of ion suppression [96, 97]. Similar results were reported by Lew and 
coworkers attesting the transferability of this methodology [98]. This CZE-ESI-MS/MS method was applied in the 
context of biosimilarity assessment. CZE-ESI-MS/MS data from approved mAbs trastuzumab and cetuximab were 
compared to their respective biosimilar candidates. Results reported the ability in a single injection of each sample 
to characterize a difference of a single amino acid between trastuzumab and the corresponding biosimilar candi-
date. Using the same datasets, every PTMs hotspots reported for these mAbs could be successfully characterized 
and relative modification levels could be compared [99]. Recent research demonstrates the relevance of using 
CZE-ESI-MS analysis to characterize the amino acid sequence of mAbs. CZE selectivity proved to be of interest 
especially by allowing the separation and successful transfer to the MS of every single peptide generated from 
tryptic digestion regardless of their chemical structure enabling complete sequence coverage in a robust manner. 
Results reported using CZE-ESI-MS/MS allow to position this method not solely as a routine analysis to confirm 
recombinant mAbs production but also as a powerful tool which could improve R&D pipeline by providing com-
prehensive data regarding the amino acid sequence and post-translational modifications. 
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5.2.2 Glycosylation characterization 
Glycosylation is one of the major critical quality attribute (CQA) of therapeutic mAbs. Glycosylation can influence 
different properties of mAbs including solubility, half-life and pharmacokinetic (PK) which are crucial considering 
their use as therapeutic treatments. Gennaro et al reported the separation and analysis of glycopeptides isolated 
from Lys-C digest using CZE-ESI-MS. In the same research article, they described the use of CZE-ESI-MS to analyze 
APTS labeled released glycan in negative ionization mode. Results showed successful characterization of the major 
N-glycosylations and six O-glycosylation sites with the possibility in some cases to evaluate the site occupancy 
[93]. Later on the same group reported the development of a method using PVA coated capillary equipped on a 
CZE-LIF/ESI-MS instrument for the analysis of APTS labeled glycans released from mAbs samples. They demon-
strated that the suitability of this method to characterize released glycan as 10 different glycoforms could be iden-
tified for the studied mAbs including afucosylated glycans and some containing sialic acid [100]. Bunz et al recently 
described the development of a CZE-ESI-MS method using a basic BGE to perform the analysis of released glycans 
either for charged native glycans as well as APTS labeled glycans in the same experiment. They were able to iden-
tify 15 different glycosylations obtained after released from a therapeutic antibody sample showing the relevance 
of the method to ease characterization of unknown glycosylation. They studied the influence of APTS labeling on 
ionization intensity determining that labeling decreases by 3 times signal intensity [101]. In parallel, Bunz and 
coworkers developed another CZE-ESI-MS employing an acidic BGE. They performed a systematic and quite com-
plete study of the different parameters of the method to determine the parameter influencing significantly glycan 
separation and proposed optimized conditions [32]. Data obtained from mAbs tryptic digest by Gahoual and 
coworkers using sheathless CE-ESI-MS/MS were also used to characterize glycosylations. By using fragmentation 
spectra of tryptic glycopeptides, they could locate the position of each glycosylation sites and perform site de-
pendent characterization integrated in the same experiment as the amino acid sequence characterization. MS/MS 
spectra recorded allowed to characterize the structure of the different glycosylation identified and intensities en-
abled estimation of relative abundance of each glycoform [96]. The same group applied this methodology in the 
context of biosimilarity assessment and demonstrated the possibility to distinguish faint differences in glycosyla-
tion profiles [99, 102].  
 
5.2.3 Middle-up analysis 
Middle-up characterization is performed by submitting therapeutic mAbs sample to limited digestion prior to anal-
ysis. This methodology is meeting recently a growing interest because it gives the opportunity to focus investiga-
tion on specific parts of the protein, Fab part or Fc part for example, while limiting the complexity which may arise 
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from the heterogeneity of the rest of the protein. Development of middle-up analysis has been made possible by 
the introduction of proteolytic enzymes particularly specific for IgG such as streptococcal endopeptidase IdeS 
[103]. Limited digestion has also the advantage of not requiring to complete proteolytic digestion which may in-
duce endogenous modifications of the mAbs during the analysis process [104]. Due to the absence of stationary 
phase and the electrophoretic mobilization of analytes during the separation, CE is a technique particularly suita-
ble for the separation of fragments generated from limited digestion of mAbs. Similarly to CZE-UV, one of the 
major issues for middle-up and intact protein analysis is on the possible protein adsorption on the inner capillary 
wall due to non-protonated silanol groups remaining. As previously described different approaches were de-
scribed to reduce protein adsorption (dynamic or permanent coating). Concerning MS detection, permanent coat-
ings as HPC or LPA are preferred. Indeed, to avoid regeneration step and possible release which can compromise 
the compatibility with MS detection, permanent coating, consisting to covalent linkage to the capillary wall, ap-
pears to be the best option. 
 
Figure 5. (a) Separation of intact Infliximab charge variants using a 23 cm APS-PEG450 coated device at approxi-
mately 600 V/cm. Identified lysine variant bands are labeled as 2-K, 1-K, and 0-K. (b) Deconvoluted mass spectra 
for each lysine variant. Glycosylation structures are labeled above the mass of each peak. Reprinted from [109]. 
Copyright (2013) American Chemical Society. 
 
Based on offline CZE-MALDI/ESI-MS instrumentation implemented, Biacchi et al could demonstrated the separa-
tion of the different type of fragments generated consequently from IdeS digestion of cetuximab using HPC capil-
lary. Therefore they were able to characterize independently the N-glycosylation sites present respectively on the 
Fc and Fd part of the mAb. Identification of 8 glycoforms for Fc fragments and 6 glycoforms for Fd fragments could 
be achieved. Additionally, described results showed in the case of Fc fragments the complete separation on lysine 
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variant species [105]. Furthermore using a similar approach, they could demonstrate the formation of dimers due 
to the IdeS digestion which revealed to be stable enough to be conserved when the analysis was performed in 
native conditions [106]. Data recently published from Zhao et al showed the development of a CZE-ESI-MS method 
applied to the analysis of reduced mAbs. They demonstrated using this method the possibility to separate the HC 
and the LC. In addition they could successfully identified a mixture composed of several reduced mAbs [107]. The 
CZE-ESI-MS method developed by Han and coworkers was used to perform a detailed middle-up characterization 
of a therapeutic IgG1 using different sample treatment. Data presented proved the separation of the HC and the 
LC when the sample was undergoing reduction. During the analysis of IdeS digests, the developed method exhib-
ited the separation of the different fragments generated from the limited digestion with the possibility to distin-
guish lysine variants. In addition, the same method was applied to analyze mAbs stability samples treated with 
IdeS followed by reduction. Results obtained for sample experiencing deamidation demonstrated the separation 
of the Fd fragment bearing a succinimide intermediate on the asparagine of interest therefore revealing the po-
tential of CZE-ESI-MS for the middle-up characterization of therapeutic mAbs [108]. 
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Figure 6. MS and MS/MS spectra of drug-loaded peptides. (a) [GEC]z + 1 payload, (b) [SCDK] + 1 payload, (c) 
[THTCPPCPAPELLG] + 1 payload and (d) [THTCPPCPAPELLG] + 2 payloads. Reprinted from [111]. Copyright (2016) 
Elsevier.  
 
5.2.4 Intact analysis 
In depth MS analysis of intact mAbs remains one of the major challenge in the context of analytical characteriza-
tion of therapeutic mAbs and their related products. CE appears as a technique with significant potential for the 
characterization of intact mAbs in concomitance with MS due to its separation principle enabling migration of 
intact proteins. Implementation of CZE-MALDI-MS method developed by Biacchi et al emphasized the possibility 
to separate intact charge variants of trastuzumab followed by MS identification [92]. Regarding CZE-ESI-MS, Han 
and coworkers detailed a method for the analysis of intact IgG1. Using PNGase F treated samples, they demon-
strated the separation and successful identification of free LC contained in IgG1 reference material [108]. Another 
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research of interest was reported by Redman et al. They described the preparation of a microchip CZE-nanoESI-
MS system enabling the analysis of intact infliximab and showed that lysine variants could be separated and char-
acterized (Figure 5). In addition the system was applied to a IgG1 drug conjugate, their findings proved the possi-
bility to distinguish non conjugated species as well as mono and di-conjugated IgG [109]. Recently, the same re-
search group used this microchip interface for the characterization of intact ADCs. Results reported show the sep-
aration of the charge variants generated from N-terminal pyroglutamic acid formation and decarboxylation for the 
unconjugated mAb. Additionally, ADC analysis demonstrated the separation of species exhibiting different number 
of conjugated drugs and the ability to determine antibody-drug ratio (DAR) values in agreement to with ESI-MS 
infusion and imaging CE analysis [110]. The introduction of ADCs is adding a layer of complexity, compared to 
conventional mAbs, regarding analytical characterization. To address the complexity originating from these mod-
ified proteins, Said and coworkers developed an analytical methodology combining ADCs analysis on the intact, 
middle-up and amino acid sequence level [111]. This methodology, alongside to comprehensive peptide backbone 
characterization, enables to determine the different species generated from the conjugation reaction and locate 
the position of the drug on the amino acid sequence (Figure 6). From a general point of view, characterization of 
intact mAbs and their related format using CE-MS analysis is currently generating great expectations therefore 
driving research into intensive development which may presage the introduction of innovative application in the 
near future 
6. CONCLUSION 
In the past decade, several hundreds of papers have been published on analytical and structural characterization 
of mAbs and related products using different strategies as chromatography, electrophoresis, and mass spectrom-
etry. As shown is this review, CE presents some clear benefits as high resolution separation, and miniaturized 
format to be widely applied to the analysis of biopharmaceuticals. CE is a technique fully suitable for the separa-
tion of proteins at different levels. CGE, cIEF, icIEF and CZE methods have been particularly relevant for the char-
acterization of size and charge variants of intact and reduced mAbs, while CE-MS appears to be a crucial analytical 
tool to assess the primary structure of mAbs in providing information about amino acid sequence, PTMs or deg-
radations as oxidation, deamidation, N-terminal pyroglutamate formation, glycosylation, sialylation or C-terminal 
lysine truncation. These methods are widely applied during the process development and the quality control of 
the drug. The robustness of some CE-based methods as CGE, cIEF, icIEF and CZE have been assessed by different 
inter-laboratory studies for the majority managed by independent biopharmaceutical companies [64, 65, 80]. The 
uniformity of protocols and the assessment of reproducibility and robustness make CE a reference method applied 
routinely for lot consistency, purity and stability in quality control laboratories of biopharmaceutical companies.  
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CE Mode 
 
Detection Sample Application BGE Cap. coating Reference 
CGE UV 200 nm IgG1 Size heterogeneity of intact mAb BC SDS-Mw gel buffer BFS [68] 
CGE LIF 488 nm, 520 nm Human IgG N-Glycan mapping (Interlaboratory) Sciex N-CHO carbohy-
drate separation gel buf-
fer 
Sciex N-CHO [34] 
CGE LIF 488 nm, 520 nm IgG Glycosylation profiling carbohydrate separation 
buffer and eCaPTM DNA 
gel 1000 
 
eCaPTM neutral [35] 
CGE LIF 587 nm, 607 nm IgG High-throughput glycosylation 
 analysis 
  [53] 
CGE LIF IgG Size heterogeneity of reduced mAb BC SDS-Mw gel buffer BFS [51] 
CGE LIF 488 nm, 560 nm IgG Stability testing, degradation testing BC SDS gel buffer BFS [52] 
CGE LIF 488 nm, 520 nm IgG High-throughput glycosylation 
 analysis 
Sciex N-CHO carbohy-
drate separation gel buf-
fer 
eCaPTM N-CHO [36] 
CGE LIF 488 nm, 520 nm mAb Glycosylation analysis BC carbohydrate separa-
tion gel buffer 
PVA [33] 
CGE UV 214 nm Rituximab and biosimilar Biosimilarity assessment 
Size heterogeneity of reduced mAb 
  [47] 
CGE UV 214 nm, 280 nm Fc-Fusion protein Characterization of aggregation BC SDS-Mw gel buffer BFS [37] 
CGE LIF 488 nm, 512 nm mAb Glycosylation profiling BC gel buffer 
AB POP-7polymer 
BFS 
PVA 
[32] 
CGE LIF 488 nm, 560 nm Trastuzumab, pertu-
zumab 
Size heterogeneity of intact and  
reduced mAb 
BC sieving gel buffer BFS [48] 
CGE LIF 488 nm, 520 nm IgG Core fucosylation analysis BC N-CHO carbohydrate 
separation gel buffer 
eCaPTM N-CHO [112] 
CGE LIF 3 humanized mAbs Size heterogeneity of reduced mAb BC SDS-Mw gel buffer  [50] 
CGE UV 220 nm mAb Protein quantification BC SDS-Mw gel buffer BFS [113] 
CGE UV 220 nm mAb and conjutated Conformational behavior 30 mM Tris pH 8.5 SDS 
(5-30 mM)  
HPC [31] 
CGE UV 280 nm vcMMAE-ADC Profiling ADC positional isomers BC SDS-Mw gel buffer BFS [54] 
CGE LIF 325 nm, 405 nm Cetuximab, infliximab, 
tocilizumab, bvacizumab, 
gemtuzumab ozogami-
cin, adalimumab 
Glycosylation analysis 100 mM Tris-borate pH 
8.3, 5% PEG 70000 
DB-1 [38] 
CGE LIF 488 nm IgG Quantitative impurity analysis BC SDS-Mw gel buffer BFS [45] 
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CGE UV 220 nm Anti-CD4 mouse IgG2a Characterization of Ricin A-chain  
immunotoxins 
Bio Rad CE-SDS buffer BFS [114] 
CGE UV IgG1 mAb purity analysis BC SDS-MW gel buffer BFS [46] 
CGE LIF 488 nm, 520 nm Ch14.18 Glycosylation analysis BC Carbohydrate label-
ing and analysis kit 
BC coated capil-
lary 
[39] 
CGE LIF 488 nm, 520 nm Mouse IgG Potentially immunogenic  
carbohydrate residues in biologics 
BC Carbohydrate separa-
tion gel buffer 
eCaPTM N-CHO [40] 
CGE LIF Mouse serum IgG 
Bovin serum IgG 
Size heterogeneity of reduced mAb 60 mM Tris-borate 0.1% 
SDS pH 8.45 
BFS [115] 
CGE LIF 488 nm, 520 nm Palivizumab, Rituximab Glycosylation analysis 100 mM Tris-CH3CO2H 
0.05% HPC pH 7.0 
DB-1 [41] 
CGE UV 220 nm Fc-Fusion protein Disulfide scambled forms during  
purification process 
BC SDS-Mw gel buffer BFS [55] 
CGE LIF 488 nm IgG1 Size heterogeneity of reduced mAb   [116] 
CGE LIF 488 nm IgG1 Glycation characterization BC sieving gel buffer BFS [117] 
CGE UV 220 nm IgG1 Size heterogeneity of reduced mAb 
under copper and high pH stress 
BC sieving gel buffer BFS [118] 
CGE LIF 488 nm, 520 nm IgG Glycosylation analysis 7.5 mM CH3CO2NH3 
25 mM H3BO3 1.5% LPA 
LPA [30] 
CGE LIF 488 nm, 520 nm IgG1 Glycosylation analysis BC Carbohydrate separa-
tion gel buffer 
eCaPTM N-CHO [43] 
CGE LIF 488 nm, 520 nm Rituximab Characterization of oligosaccharides 100 mM Tris-CH3CO2H 
0.05% HPC pH 7.0 
DB-1 [42] 
CGE UV 220 nm Goat IgG, Rat IgG Size heterogeneity of reduced mAb BC SDS-MW gel buffer BFS [49] 
CGE UV 220 nm mAb Size heterogeneity of reduced mAb BC sieving gel buffer BFS [119] 
CGE UV 220 nm IgG2 Size heterogeneity of reduced mAb BC SDS-MW gel buffer BFS [120] 
CGE UV 220 nm IgG2 Disulfide isomer heterogeneity BC SDS-MW gel buffer BFS [121] 
CGE LIF 543.5 nm mAb 8E11 Quantitative study of stereospecific 
binging of mAb to BPDE-dG adducts 
14 mM Tris 108 mM gly-
cine 10.5 mM CH3CO2H 
pH 7.5 
30 mM Tris 160 mM gly-
cine pH 8.5 
BFS [122] 
CGE UV 220 nm mAb1 Size heterogeneity of reduced mAb 25 mM citrate-phos-
phate 
1% SDS pH 6.5 
BFS [123] 
iCIEF UV 280 nm Avastin and biosimilar Charge heterogeneity of intact mAb Amph: 3-10:8-10.5 (1:1) 
+0.35% MC  
 [124] 
CIEF UV IgG1 Glycosylation analysis   [63] 
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CIEF  Human IgG1 Charge heterogeneity of intact mAb Amph: 3-10:5-8 (4:2) 
Anol: 0.04M H3PO4 
Cath: 0.08M NaOH 
FC, LPA [62] 
iCIEF UV 280 nm IgG1 Charge heterogeneity of intact mAb  FC [68] 
iCIEF UV 280 nm PBD-ADC, vcMMAE-ADC Charge heterogeneity of intact mAb 
Heat-stress stability  
Amph: Pharmalyte FC [72] 
iCIEF UV 280 nm CD20 and CD38 mAb Characterization of C-terminal Lys  FC [66] 
iCIEF UV 280 nm mAb Charge heterogeneity of reduced 
mAb 
  [125] 
CIEF UV 280 nm Trastuzumab, biosimilar Charge profiling, stability testing of 
biosimilar 
Amph: 3-10:8-10.5 
Anol: 200 mM H3PO4 
Cath: 300 mM NaOH 
FC [61] 
iCIEF UV 280 nm Human IgG Charge heterogeneity of intact mAb Amph: 3-10, 
0.35%HPMC 
HPMC [84] 
CIEF UV 280 nm MAK-33 IgG Robust protein reagent characteriza-
tion 
Amph: 3-10 
Anol: 200 mM H3PO4 
Cath: 300 mM NaOH 
PVA [60] 
CIEF UV 280 nm Cetuximab 
Trasbuzumab 
Bevacizumab 
Quality assurance based on charge 
variants.  
Comparaison with microchipIEF 
Amph: 3-10 
Anol: 200 mM H3PO4 
Cath: 300 mM NaOH 
+0.04% HPMC both 
HPMC [69] 
iCIEF UV 280 nm Trastuzumab, pertu-
zumab 
Charge heterogeneity of intact and 
reduced mAb 
Amph: 3-10 
Anol: 80 mM H3PO4 
Cath: 100 mM NaOH 
+0.1% HPMC both 
FC [48] 
iCIEF  3 humanized mAbs Charge heterogeneity of reduced 
mAb 
  [50] 
CIEF BC Protocol Conbercept Structural characterization BC Protocol BC Protocol [71] 
CIEF UV 280 nm IgG Charge heterogeneity of intact mAb Amph: 5-8:8-10.5 (3:7) 
Anol: 0.08M H3PO4 
Cath: 0.1M NaOH 
+0.1% HPMC both 
FC [57] 
iCIEF UV 280 nm mAb 
Fc-fusion protein 
Charge heterogeneity of intact mAb Amph: 3-10, 4-6.5, 8-
10.5 
Anol: 0.08M H3PO4 
Cath: 0.1M NaOH 
+0.1% HPMC both 
FC [70] 
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iCIEF UV 280 nm Anti-α-antitrypsin mouse 
mAb 
Charge heterogeneity of intact mAb 
Interlaboratory study 
Amph: 5-8 
Anol: 0.08M H3PO4 
Cath: 0.1M NaOH 
+0.1% HPMC both 
FC [65] 
iCIEF UV 280 nm Ch14.18 Charge heterogeneity of intact mAb 
 
Amph: 5—8:8-10.5 
25/75 
Anol: 0.08M H3PO4 
Cath: 0.1M NaOH 
 [39] 
CIEF UV 280 nm mAb R1 
mAb HA 
Charge heterogeneity of intact mAb 
 
Amph: 3-10, 8-10.5 
Anol: 0.2M H3PO4 
Cath: 0.3M NaOH 
PVA [59] 
CIEF UV 280 nm IgG1 Charge heterogeneity of intact mAb 
Interlaboratory study 
Amph: 5-8 
Anol: 0.2M H3PO4 
Cath: 0.3M NaOH 
BC neutral [64] 
iCIEF UV 280 nm mAb 
 
High throughput profiling of charge 
heterogeneity 
Amph: 3-10 
Anol: 0.08M H3PO4 
Cath: 0.1M NaOH 
neutral [82] 
iCIEF UV 280 nm  Human mAb Amino acid substitution identification Amph: 5-8, 8-10.5 FC [126] 
iCIEF UV 280 nm Fab fragment of human 
mAb 
Identification of isomerization and 
racemization of aspartate in the Asp-
Asp motifs 
Amph: 3-10:6.7-7.7 (1:1) 
Anol: 0.08M H3PO4 
Cath: 0.1M NaOH 
+0.1% HPMC both 
FC [127] 
iCIEF UV IgG1 IgG4 Net Charge assessment Amph: 3-10:8-10.5 
15/85 
 [128] 
CIEF UV 280 nm Gemtuzumab ozogamicin Charge heterogeneity of intact mAb 
with a cytotoxic antitumor antibiotic 
 
Amph: 3-10 
Anol: 0.2M H3PO4 
Cath: 0.3M NaOH 
DB-1 [73] 
CIEF UV 280 nm IgG2 Charge heterogeneity of intact mAb Amph: 3-10 LPA [67] 
CZE UV 280 nm Avastin and biosimilar Charge heterogeneity of intact mAb 500 mM EACA/0.1M HCl 
2 mM TETA pH 5.7 
0.05% HPMC 
BFS [124] 
CZE UV 200 nm Anti-HAS-mAb Determination of binding constant 50 mM borate pH 9.3 BFS [129] 
CZE UV 214 nm Fc1 or anti-CD40 IgG1 Characterization of Fc1 aggregation  eCaPTM amine [130] 
CZE UV 214 nm IgG1 Charge heterogeneity of intact mAb 
Interlaboratory study 
400 mM EACA/CH3CO2H 
2 mM TETA pH 5.7 
0.05% HPMC 
HPMC [80] 
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CZE UV 214 nm Cetuximab, beva-
cizumab, rituximab, tras-
tuzumab 
Rapid identification fo mAb 75 mM phosphate  
0-1.5mM perchloric acid  
0.15 mMpolysorbate 80 
PB [86] 
CZE UV 214 nm Trastuzumab, pertu-
zumab 
Charge heterogeneity of intact and 
reduced mAb 
40 mM EACA/CH3CO2H 
0.2% HPMC pH 4.5 
HPMC [48] 
CZE UV 200 nm Inflixumab, rituximab, 
bevacizumab, cetuximab, 
tocilizumab 
Charge heterogeneity of intact mAb 400 mM EACA/CH3CO2H 
0.2% Tween 20 pH 5.7 
PB-DS-PB 
UltratrolTM LN 
UltratrolTM HR 
HPC 
[77] 
CZE UV 214 nm Rituximab, trastuzumab 
and biosimilar, ranibi-
zumab, bevacizumab,In-
fliximab and biosimilar 
Charge heterogeneity of intact mAb 200 mM EACA/CH3CO2H 
30 mM CH3CO2Li pH 4.8 
150 mM EACA/CH3CO2H 
20 mM CH3CO2Li pH 5.5 
0.05 HPMC 
HPMC [83] 
CZE UV 214 nm IgG1 Determination of Charge variants 20 mM CH3CO2Na  
2 mM TETA pH 6.0 
03% PEO 
PEO [81] 
CZE UV 214 and 254 nm Bevacizumab, ranibi-
zumab 
Effective electrophoretic mobilities 
and charges 
0.016-0.16 mM PBS pH 
7.4  
BFS [131] 
CZE UV 214 nm IgG Rapid analysis of Charge heterogene-
ity of intact mAb 
400 mM EACA/CH3CO2H 
2 mM TETA pH 5.7 
0.05% HPMC 
HPMC [79] 
CZE UV 214 nm mAb 
 
High throughput profiling of charge 
heterogeneity 
20 mM EACA/CH3CO2H 
0.01% polysorbate 20 pH 
4.4, 0.05% HPMC 
neutral [82] 
CZE UV 214 nm IgG Charge heterogeneity of intact mAb 
and disulfide isomers 
600 mM EACA/CH3CO2H 
0.1% HPMC pH 5.5 
HPMC [78] 
MZE  IgG1, IgG4 Size heterogeneity of reduced mAb   [132] 
ME-SDS LIF 635 nm, 700 nm IgG Charge heterogeneity of mAb 
Stability testing, degradation testing 
HT protein express gel 
matrix + fluorescent dye 
BFS [52] 
MZE UV 214 nm Human IgG Charge heterogeneity of intact mAb 400 mM EACA/CH3CO2H 
2 mM TETA pH 5.7 
0.05% HPMC 
HPMC [84] 
MZE Chemiluminescence Anti-cortisol mouse Ab Homogeneous immunoassay of corti-
sol 
10 mM phosphate  
+ 0.08% Tween 20 
+ 1% luminol 
 [133] 
MIEF UV 280 nm Cetuximab 
Trasbuzumab 
Quality assurance based on charge 
variants.  
Amph: 3-10 
Anol: 40 mM C4H7NO4 
HPMC [69] 
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Bevacizumab Comparaison with CIEF Cath: 100 mM NaOH 
+0.1% HPMC both 
MZE  IgG1, IgG2 Glycosylation analysis   [134] 
MZE UV 280 nm mAb 
 
High throughput profiling of charge 
heterogeneity 
50 mM CH3CO2Na 
+ 0.1% polysorbate 20 
+ 0.2% HPMC 
HPMC [82] 
MZE Chemiluminescence Mouse anti-T4 mAb Immunoassay 10 mM PBS pH 10.2 Brij 35 [135] 
MZE  IGN311 Impurity testing   [85] 
CZE-MS ESI-QTOF-MS Brentuximab vedotin 
vcMMAE-ADC 
Intact, middle-up and bottom-up 
characterizaiton 
10% CH3CO2H BFS [111] 
MZE-MS ESI-QTOF-MS ADC Characterization of intact ADC 10% 2-propanol 
+ 0.2% CH3CO2H 
PEG, APS [110] 
CZE-MS ESI-QTOF-MS/MS Trastuzumab Asparagine deamidation and iso 
Apartic acid isomerization characteri-
zation 
10% CH3CO2H BFS [97] 
CZE-MS ESI-QTOF-MS Cetuximab Fc/2 dimers characterization Inlet vial: 200 mM EACA 
+ 25 mM CH3CO2Na pH 
5.7 
Outlet vial: 25 mM 
CH3CO2Na pH 5.7 
HPC [106] 
CZE-MS ESI-Orbitrap-MS Anti-human IgG4 Charge heterogeneity of reduced 
mAb 
0.1%  COOH 
SL: 10%CH4O/0.5%COOH 
LPA [107] 
CZE-MS ESI-Orbitrap-MS Human mAb Host cell Impurities detection 0.1%  COOH 
SL: 10%CH4O/0.5%COOH 
LPA [136] 
       
MZE-MS ESI-TOF-MS Inflixumab, IgG2 Charge heterogeneity of intact mAb 100 mM PBS 
+ 10 g/L NHS-PEG  
APS [109] 
CZE-MS MALDI-TOF-MS Cetuximab Glycoform characterization 
Middle up analysis 
Inlet vial: 200 mM EACA 
+ 25 mM CH3CO2Na pH 
5.7 
Outlet vial: 25 mM 
CH3CO2Na pH 5.7 
HPC [105] 
CZE-MS ESI-QTOF-MS/MS Trastuzumab, cetuximab 
2 other mAbs 
Sequence coverage, glycosylation and 
PTMs characterization 
10% CH3CO2H BFS [96] 
CZE-MS ESI-Orbitrap-MS/MS Trastuzumab Glycosylation profiling 10% CH3CO2H BFS [98] 
CZE-MS ESI-QTOF-MS/MS Trastuzumab, cetuximab 
Biosimilar candidates 
Biosimilarity assessment 10% CH3CO2H BFS [99] 
CZE-MS MALDI-TOF-MS Trastuzumab Charge heterogeneity of intact mAb 400 mM EACA HPC [92] 
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MALDI-TOF-MS/MS Peptide mapping 0.5% CH3CO2H pH 5.7 
 
Micro-
chip-LC-
CE-MS 
ESI-TOF-MS IgG2 Glycosylation analysis  APTES [137] 
CZE-MS ESI-QTOF-MS Trastuzumab Sequence coverage, glycosylation and 
PTMs characterization 
10% CH3CO2H BFS [95] 
CZE-MS ESI-TOF-MS mAb Glycosylation profiling 40 mM EACA, 131 
mM acetic acid pH 4 
PVA [101] 
CZE-MS ESI-QTOF-MS IgG Glycosylation profiling 100 mM EACA, 700 mM 
ammonia in 30:70 H2O/ 
CH4O pH 10 
BFS [32] 
CIEF-MS ESI-Orbitrap-MS Human IgG Host cell protein analysis Amph: 3-10 
Anol: 0.1% COOH pH 2.5 
Cath: 0.3% NH3OH pH 11 
LPA [58] 
CZE-MS ESI-TOF-MS mAb Peptide mapping 
CE-MS interfaces comparison 
10% CH3CO2H PVA [94] 
CZE-MS ESI-TOF-MS IgG1 Charge heterogeneity of reduced 
mAb 
 Middle up analysis 
10%-30% CH3CO2H  
SL: 50%CH4O/0.5%COOH 
LPA [108] 
       
       
 
Table 1. Application and CE methods for the analysis of IgG, biosimilars, Fc-fusion proteins and ADCs in the years 2010-2015 
Abbreviation: PBS phosphate buffer saline; EACA ε-amino caproic acid; TETA triethylenetetramine; BC Beckman Coulter; AB Applied Biosystems; BFS bare fused silica; LPA 
linear polyacrylamide; PVA polyvinyl alcohol; HPMC hydroxypropyl-methyl cellulose; HPC hydroxypropyl cellulose; FC fluorocarbon; PB polybren; DS dextran sulfate; PEO 
Polyethylene oxide; APS aminopropylsilane; APTES aminopropyltriethoxysilane 
 
 
 
